Advisory committees under review
This article was originally published in The Tan Sheet
Executive Summary
The Center for Drug Evaluation & Research will review its advisory committee meeting system over the next year to establish best practices surrounding the process, FDA announces May 5. The internal assessment, led by senior management from CDER's Advisors & Consultants Staff, is part of FDA's broader initiative to modernize management of the new drug review process. The evaluation will look at the process for nominating members and choosing consultants, developing competing products lists, screening for conflicts of interest and the role of special government employees outside of advisory committee meetings. The advisory committee system has been a topic of recent public scrutiny. In January, Steve Nissen (Cleveland Clinic Foundation) criticized committees for lacking the means and courage to properly advise FDA on issues of drug safety...
You may also be interested in...
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market
Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.